statistiche ricercatore

Continente	#
NA - Nord America	939
AS - Asia	784
EU - Europa	540
AF - Africa	55
SA - Sud America	29
OC - Oceania	2
Continente sconosciuto - Info sul continente non disponibili	1
Totale	2.350

Nazione	#
US - Stati Uniti d'America	912
VN - Vietnam	344
CN - Cina	166
SG - Singapore	156
GB - Regno Unito	140
IT - Italia	90
DE - Germania	71
SE - Svezia	50
HK - Hong Kong	40
RU - Federazione Russa	32
FR - Francia	31
CA - Canada	25
IN - India	24
TG - Togo	22
BR - Brasile	21
CI - Costa d'Avorio	19
UA - Ucraina	19
BE - Belgio	17
IE - Irlanda	17
JP - Giappone	15
NL - Olanda	15
EE - Estonia	11
CH - Svizzera	10
ZA - Sudafrica	10
FI - Finlandia	8
BG - Bulgaria	7
LT - Lituania	6
TW - Taiwan	6
ID - Indonesia	5
RO - Romania	5
TH - Thailandia	5
AR - Argentina	4
JO - Giordania	4
KR - Corea	4
PH - Filippine	4
PK - Pakistan	4
PL - Polonia	4
AU - Australia	2
CL - Cile	2
GR - Grecia	2
IR - Iran	2
A2 - ???statistics.table.value.countryCode.A2???	1
AO - Angola	1
BD - Bangladesh	1
BY - Bielorussia	1
CO - Colombia	1
DO - Repubblica Dominicana	1
EC - Ecuador	1
ES - Italia	1
GH - Ghana	1
JM - Giamaica	1
KG - Kirghizistan	1
LV - Lettonia	1
NG - Nigeria	1
PS - Palestinian Territory	1
RS - Serbia	1
SA - Arabia Saudita	1
SC - Seychelles	1
SI - Slovenia	1
TR - Turchia	1
Totale	2.350

Nome	#
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2.	380
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.	245
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases	232
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor	226
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy	209
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines	196
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis	184
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.	184
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.	184
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy	184
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas	169
Totale	2.393

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	33	0	0	0	0	0	0	0	0	0	8	12	13
2021/2022	217	13	4	24	9	23	11	7	16	6	15	60	29
2022/2023	320	35	56	17	52	19	18	8	18	39	16	27	15
2023/2024	82	3	15	3	11	8	11	5	14	1	4	3	4
2024/2025	284	25	29	27	13	39	28	11	15	1	17	22	57
2025/2026	780	228	44	48	54	72	32	55	17	171	59	0	0
Totale													2.393

CRIS Current Research Information System